Catalyst Pharmaceutical Partners Provides Update on FIRDAPSE(TM) Progress

Catalyst Pharmaceutical Partners Provides Update on FIRDAPSE(TM) Progress

CORAL GABLES, Fla., June 27, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on
the development and commercialization of novel prescription drugs targeting
rare (orphan) neuromuscular and neurological diseases, today provided an
update on its progress with its lead investigational product, FIRDAPSE^TM.

"Over the past six months, we have made great strides in our advancement of
Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). We
have recently achieved several important milestones in our development plan,
and we therefore feel that this is an appropriate time to report our progress
to investors and other stakeholders," said Patrick J. McEnany, Chief Executive
Officer of Catalyst Pharmaceutical Partners, Inc.

Firdapse Progress Report To Date:

In October 2012, Catalyst acquired the North American rights to Firdapse, a
proprietary form of amifampridine phosphate (3-4 diaminopyridine or 3,4-DAP),
from BioMarin Pharmaceutical Inc. ("BioMarin"). As part of that transaction,
BioMarin made a $5 million strategic investment in Catalyst to help fund the
development of Firdapse. Firdapse was approved in December 2009 by the
European Medicines Agency for the treatment of Lambert-Eaton Myasthenic
Syndrome (LEMS), a rare and sometimes fatal autoimmune disease characterized
by muscle weakness. Firdapse has been granted orphan drug designation by the
U.S. Food & Drug Administration, (FDA) for the treatment of LEMS, making the
product eligible to obtain seven-year marketing exclusivity if Catalyst is the
first pharmaceutical company to obtain approval of an NDA for its formulation
of amifampridine.

Catalyst has recently completed the following activities in the development of
Firdapse for LEMS:

  1. Completed transfers from BioMarin of the active IND in the U.S. and
  Clinical Trial Applications in France, Germany, Italy, Poland and Spain to
  Catalyst sponsorship;

  2. Retained a Clinical Research Organization (CRO) with a global footprint
  and experience in the management of clinical trials of investigational drug
  products for the treatment of neurological diseases to execute the Phase III
  trial for Catalyst;

  3. Hired an experienced Vice President of Clinical Operations to provide
  day-to-day oversight of the Phase III trial;

  4. Engaged a regulatory consultant with relevant FDA experience to conduct
  background research and provide discussions and opinions bearing on the
  regulatory aspects of the company's drug development program for Firdapse;

  5. Completed transfer of the management and oversight of the ongoing Phase
  III registration trial from BioMarin to Catalyst and our CRO (For further
  details on this trial, please go to: www.clinicaltrials.gov; Search
  "amifampridine phosphate");

  6. In addition to the initial 7 sites active at the time of acquisition, we
  have identified, are contracting with, and obtaining IRB/Ethics Committee
  approvals at, 18 prequalified sites with approximately 75 prospective LEMS
  patients currently under treatment located in 9 countries and the U.S. to
  participate in our clinical trial:

    *4 additional trial sites have been initiated and are now ready to screen
      potential trial subjects;
    *we expect that more than half of remaining trial sites will be initiated
      by the end of July; and
    *we expect that all new trial sites will be initiated before the end of
      September;

  7. Conducted a Data Monitoring Committee meeting, at which continuation of
  the trial under the present protocol was recommended; and

  8. Retained a commercial operations consultant to assist in development of a
  strategic plan and to identify pre-launch activities that will be required
  for a successful launch of Firdapse upon FDA approval.

  Based on this progress and its patient enrollment projections, Catalyst
  continues to expect:

    *to complete enrollment of 36 subjects in the Phase III trial during the
      4^th quarter of 2013; and
    *to report top-line results from the double-blind portion of the Phase
      III trial during the second quarter of 2014.

  Assuming positive results are obtained from the Phase III trial, Catalyst
  expects:

    *to submit an NDA for Firdapse in the first quarter of 2015;
    *to obtain approval from the FDA of such NDA by the end of 2015; and
    *to commercially launch Firdapse in the first half of 2016.

About LEMS

Lambert-Eaton Myasthenic Syndrome, LEMS, is a rare autoimmune disease that can
be severely disabling, with the primary symptom of muscle weakness. The
weakness is generally more marked in the proximal muscles, particularly of the
legs and trunk. Other problems include reduced reflexes, drooping of the
eyelids, facial weakness and problems with swallowing. Patients often report
dry mouth, impotence, constipation and feelings of light headedness on
standing. These problems can be life threatening when the weakness involves
respiratory muscles. The muscle weakness in LEMS is caused by autoantibodies
to voltage gated calcium channels, which cause a reduction in the amount of
acetylcholine released from nerve terminals. The prevalence of LEMS is
estimated at approximately 3,000 patients in the United States and Canada.
Approximately 50 percent of LEMS patients diagnosed have small cell lung
cancer. Patients with LEMS typically present with fatigue, muscle pain and
stiffness. A diagnosis of LEMS is generally made on the basis of clinical
symptoms, electromyographic and compound muscle action potential (CMAP)
testing and where available, the presence of autoantibodies against voltage
gated calcium channels.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company
focused on the development and commercialization of prescription drugs
targeting rare (orphan) neuromuscular and neurological diseases, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's
Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial. Catalyst is also developing a potentially safer and more potent
vigabatrin analog (designated CPP-115) to treat infantile spasms, and
epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette's Syndrome,
and movement disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
the Company's actual results in future periods to differ materially from
forecasted results. A number of factors, including the timing of adding
additional sites to the Phase III trial, the timing of completion of the
enrollment of all trial subjects who will participate in the Phase III trial,
the timing of the receipt of the top-line results from the double-blind
portion of the Phase III trial, whether any of the Company's product
candidates will ever be approved for commercialization, and those factors
described in the Company's filings with the U.S. Securities and Exchange
Commission (SEC), could adversely affect the Company. Copies of the Company's
filings with the SEC are available from the SEC, may be found on the Company's
website or may be obtained upon request from the Company. The Company does not
undertake any obligation to update the information contained herein, which
speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com